Telomir-Zn Preclinical Data Published, Showing Efficacy in Type 2 Diabetes Model
TELO sits 19% above its 52-week low of $1.05.
Summary
Telomir Pharmaceuticals announced the peer-reviewed publication of preclinical data for Telomir-Zn, showing positive results in a Type 2 diabetes model, further validating its mechanism of action and expanding its potential therapeutic scope.
Key Events · Product Development and Regulatory · TELO
-
Preclinical Data Published
Peer-reviewed preclinical data for Telomir-Zn was published in Biomedicine & Pharmacotherapy.
-
Efficacy in Type 2 Diabetes Model
Telomir-Zn demonstrated dose-dependent improvements in fasting blood glucose, glucose tolerance, and insulin resistance in a diet-induced zebrafish model of Type 2 diabetes.
-
Mechanism of Action Validated
The findings provide additional peer-reviewed evidence supporting Telomir-Zn's mechanism of action through modulation of intracellular metal homeostasis.
-
Expanded Therapeutic Potential
This publication expands the scientific foundation for Telomir-Zn, which has existing IND clearance for a Phase 1/2 clinical trial in triple-negative breast cancer.
Analysis · TELO · Life Sciences
This 8-K announces the peer-reviewed publication of preclinical data for Telomir-Zn, demonstrating its ability to restore glucose homeostasis and reduce insulin resistance in a Type 2 diabetes model. While preclinical, this expands the potential applications of Telomir-Zn beyond its primary clinical focus in triple-negative breast cancer and provides further scientific validation for its mechanism of action. This is the second such publication in 2026, reinforcing the scientific foundation of the company's lead program.
At the time of this filing, TELO was trading at $1.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $86.7M. The 52-week trading range was $1.05 to $3.10. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.